Vaccine potential of ESAT-6 protein fused with consensus CD4 T-cell epitopes of PE/PPE proteins against a highly pathogenic Mycobacterium tuberculosis strain HN878.

08:00 EDT 9th June 2018 | BioPortfolio

Summary of "Vaccine potential of ESAT-6 protein fused with consensus CD4 T-cell epitopes of PE/PPE proteins against a highly pathogenic Mycobacterium tuberculosis strain HN878."

Pro-Glu/Pro-Pro-Glu (PE/PPE) family proteins in Mycobacterium tuberculosis (Mtb) are contributors to pathogenesis and immune evasion. These proteins have a unique structure in which the sequence is conserved. We investigated the vaccine potential of ESAT-6 fused with the consensus CD4 T-cell epitopes of PE/PPE proteins against a highly pathogenic Mtb strain HN878 in a murine model.We selected the consensus CD4 T-cell epitopes of PE/PPE proteins by multiple alignments and by investigating their IFN-γ response during Mtb infection, and produced their fused ESAT-6 vaccine antigens. Our results showed that an increased immune response was observed in the PE/PPE peptide + ESAT-6 protein immunization group compared with that in the ESAT-6 only immunization group. After challenging with Mtb, we observed induced CD4 T-cells secreting double-positive cytokine IL-2/IFN-γ, which is associated with protective T-cell immunity. Also, lower numbers of colony-forming units were observed in the spleen of the fusion protein immunization groups than in the single ESAT-6 group. Thus, conjugation of the consensus CD4 T-cell epitopes in N terminus of PE/PPE to vaccine antigens could potentially increase the protective efficacy of as a subunit vaccine.


Journal Details

This article was published in the following journal.

Name: Biochemical and biophysical research communications
ISSN: 1090-2104


DeepDyve research library

PubMed Articles [35087 Associated PubMed Articles listed on BioPortfolio]

Immunological characteristics of Mycobacterium tuberculosis subunit vaccines immunized through different routes.

Tuberculosis is chronic infectious disease caused by Mycobacterium tuberculosis (M.tb) that is prevalent worldwide. Several specific antigens, such as Antigen 85B (Ag85B) and 6 kDa early secretory a...

Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence.

H1N1, one of the most prevalent influenza A virus subtypes affecting the human population, can cause infections varying from mild respiratory syndrome to severe pneumonia. The current H1N1 vaccine nee...

In situ removal of consensus dengue virus envelope protein domain III fused to hydrophobin in Pichia pastoris cultures.

This work describes a novel strategy for the integrated expression and purification of recombinant proteins in Pichia pastoris cultures. Hydrophobins can be used as fusion tags, proteins fused to them...

Conserved epitopes in variants of amastin protein of Trypanosoma cruzi for vaccine design: A bioinformatics approach.

Chagas disease caused by protozoan parasite Trypanosoma cruzi is endemic disease in South and Central American countries but due to migrating human populations it has shown emergence in Europe, North ...

Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect.

Soluble PD-1 (sPD1) can bind with ligands PD-L1/PD-L2 on the surface of dendritic cells (DCs). Therefore, a sPD1 vaccine fused with an immunogen can increase T cell activation against cancer. Here, we...

Clinical Trials [14276 Associated Clinical Trials listed on BioPortfolio]

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

The purpose of this study is to evaluate the safety profile of CAF01, administering 50 µg Ag85B-ESAT-6 alone and 50 µg Ag85B-ESAT-6 with three escalating CAF01 dose levels, to four group...

Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF

The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimu...

The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma

The main purpose of this study is to test the safety of dendritic cell tumor fusion study vaccine and to determine the type and severity of any side effects associated with this study vacc...

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory. Only part of the virus's DNA ...

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cau...

Medical and Biotech [MESH] Definitions

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)

A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)

Quick Search


DeepDyve research library

Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Searches Linking to this Article